id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2025-E-0483-0006,FDA,FDA-2025-E-0483,Determination of Regulatory Review Period for Purposes of Patent Extension; ALYFTREK,Notice,Determinations,2026-02-13T05:00:00Z,2026,2,2026-02-13T05:00:00Z,2026-04-15T03:59:59Z,2026-02-13T19:46:46Z,2026-02968,1,0,09000064b91aa742
FDA-2025-E-0483-0005,FDA,FDA-2025-E-0483,Letter to U.S. Patent and Trademark Office,Other,Letter(s),2025-12-03T05:00:00Z,2025,12,2025-12-03T05:00:00Z,,2025-12-03T18:04:27Z,,0,0,09000064b90aac61
FDA-2025-E-0483-0004,FDA,FDA-2025-E-0483,Letter from U.S. Patent and Trademark Office to FDA CDER,Other,Letter(s),2025-11-05T05:00:00Z,2025,11,2025-11-05T05:00:00Z,,2025-11-05T21:49:52Z,,0,0,09000064b906919e
FDA-2025-E-0483-0003,FDA,FDA-2025-E-0483,Letter from FDA CDER to U.S. Patent and Trademark Office,Other,Letter(s),2025-10-10T04:00:00Z,2025,10,2025-10-10T04:00:00Z,,2025-10-10T22:12:27Z,,0,0,09000064b9003145
FDA-2025-E-0483-0001,FDA,FDA-2025-E-0483,Letter from U.S. Patent and Trademark Office to FDA CDER,Other,Letter(s),2025-02-28T05:00:00Z,2025,2,2025-02-28T05:00:00Z,,2025-02-28T18:08:17Z,,0,0,090000648698fa10
FDA-2025-E-0483-0002,FDA,FDA-2025-E-0483,"Patent Extension Application from Finnegan, Henderson, Farabow, Garrett & Dunner, L.L.P. (on behalf of Vertex Pharmaceuticals (Europe) Limited)",Other,Application,2025-02-28T05:00:00Z,2025,2,2025-02-28T05:00:00Z,,2025-02-28T18:10:03Z,,0,0,090000648698fa11